Elizabeth Dudnik

11PUBLICATIONS
13CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer diagnosisHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Aug 26, 2026
De Novo Actionable Genomic Alterations in High-Grade Pulmonary Neuroendocrine Carcinomas: Therapeutic Implications of Targeted Treatment.

|May 04, 2026
The Impact of Minimal Residual Disease (MRD) Testing on the Decision-Making Process in Non-Small-Cell Lung Cancer (NSCLC).

|Mar 27, 2026
Natural Language Processing-Assisted Incidental Pulmonary Nodule Evaluation Program: Impact on Lung Cancer Outcomes.

Noa Tamam Shenholz, Keren Hod, Liat Toderis

|Apr 04, 2023
Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study.

Oded Icht, Avi Leader, Erez Batat

|May 14, 2022
FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC).

Ari Raphael, Elizabeth Dudnik, Dov Hershkovitz

|Mar 19, 2022
ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data.

Mor Moskovitz, Elizabeth Dudnik, Sivan Shamai

Pageof 2

Frequent Collaborators

2 joint publications

Roni Gillis

1 joint publications

Chul Kim

1 joint publications

Stephen V Liu

1 joint publications

Ilan Shelef